Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Targeted Medical Pharma, Inc. (TRGM)
Los Angeles, CA, US
Targeted Medical Pharma, Inc., a specialty pharmaceutical company, doing business as Physician Therapeutics, develops and commercializes amino acid based medications to physicians, pharmacies, and patients in the United States. It offers a line of patented amino acid based medical food products, dietary supplements, and generic drugs primarily for the treatment of metabolic syndrome/obesity; sleep disorders associated with anxiety; hypertension; viral infections; cognitive disorders/fatigue; sleep disorders associated with depression, fibromyalgia, and PTSD; pain disorders and inflammatory conditions/fibromyalgia; osteoarthritis and joint disorders; and peripheral neuropathy. The company also provides a proprietary billing process and supporting software (PDRx) that facilitates physician dispensing; provides inventory control; and assists regulatory reporting. In addition, it offers billing and collection services relating to its products on behalf of dispensing physician clients to private insurance and workers’ compensation insurance. Targeted Medical Pharma, Inc. distributes its products through a network of distributors and an internal sales force that sells products directly to dispensing physician clients. The company was formerly known as Targeted Medical Foods and changed its name to Targeted Medical Pharma, Inc. in 2006. Targeted Medical Pharma, Inc. was founded in 1996 and is headquartered in Los Angeles, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -90.00% | -90.00% | -90.00% | -90.00% | -90.00% | -90.00% | -99.95% | -99.94% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-26.0% Q4'15: -9.0% (vs Q4'14)
-
EPS growth Medical - Pharmaceuticals: +20.2%+26.7% ★ Q4'15: +61.6% (vs Q4'14)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-32.8% Q4'15: +5.9% (vs Q4'14)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-36.0% Q4'15: -28.5% (vs Q4'14)
-
ROIC Medical - Pharmaceuticals: +6.1%— Q4'15: +19.0% (vs Q4'14)
-
Share dilution Medical - Pharmaceuticals: +0.0%+3.2% Q4'15: +2.4% (vs Q4'14)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-3.18× Q4'15: -4.22× (vs Q4'14)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-03-04 | DEWALD MAURICE J | Director | A-Award | A | Options to Purchase Common Stock | 100,000 | 0.05 | 5.0K | 250,000 | — | ↗ |
| 2013-07-22 | Gottlieb Scott | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-07-22 | DEWALD MAURICE J | Director | A-Award | A | Option to Purchase Common Stock | 25,000 | 1.02 | 25.5K | 25,000 | — | ↗ |
| 2013-03-01 | DEWALD MAURICE J | Director | A-Award | A | Option to Purchase Common Stock | 50,000 | 1.50 | 75.0K | 50,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kim Giffoni | Executive Vice President of Foreign Sales | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TRGM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
